Robert I Blum Sells $471K of Cytokinetics Inc (CYTK) — SEC Form 4, Nov 02, 2026

Open-Market Net Sale · SEC Form 4

−$471,075

10b5-1 Plan

Reporting Owner

Robert I Blum

CEO

TXN 2026-11-02 · FILED 2026-11-02

Equity Position 290K sh 290,210 → 290,210

Filing Lag 0 business days within 2-day SEC deadline

Form 4 · Statement of Changes in Beneficial Ownership

Cytokinetics Inc

CYTK CIK 0001061983

Reporting Owner

Name	Relationship
Robert I Blum CIK 0001288859	Director CEO

Robert I Blum at Cytokinetics Inc Full insider history

Bought (12 mo) —

Sold (12 mo) $17,620,182

More from this insider at Cytokinetics Inc

Non-Derivative Securities Transactions

Title	Date	Type	Shares	Price	Net Total	Post-Txn	Ownership
Common Stock	2026-11-02	M - Exercise 10b5-1	7,500 A	$10.60	+$79,500	286,044	Direct
Common Stock	2026-11-02	S - Sale 10b5-1	7,500 D	$62.81	-$471,075	278,544	Direct

Derivative Securities Transactions

Title	Strike	Date	Type	Shares	Price	Expiration	Underlying	Ownership
Non-Qualified Stock Option (Right to Buy)	$10.60	2026-11-02	M - Exercise 10b5-1	7,500 D	$0.00	2027-02-28	7,500 Common Stock	Direct

Non-Derivative Holdings

Title	Shares Held	Ownership
Common StockF1	2,083	Indirect by Trust 1. Beneficial Ownership disclaimed.
Common StockF2	2,083	Indirect by Trust 2. Beneficial Ownership Disclaimed.
Common Stock	0	Indirect by Trust 3. Beneficial Ownership Disclaimed.

Footnotes (2)

F1: Shares held by The Bridget Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares. Show more
F2: Shares held by The Brittany Blum 2003 Irrevocable Trust, of which reporting person is a co-trustee. Reporting person disclaims any beneficial ownership interest in the Shares. Show more

Institutional Holders

Largest by reported value

5%+ Holders · 13D/G 4 filers

Latest Schedule 13D/G per filer; stakes the filer reported closed are left out.

Other insiders at Cytokinetics Inc

GET /v1/forms/4/0001061983-26-000107 API docs